J Korean Med Sci.  2024 May;39(17):e154. 10.3346/jkms.2024.39.e154.

Toxic Shock Syndrome (TSS) Caused by Group A Streptococcus: Novel Insights Within the Context of a Familiar Clinical Syndrome

• Kim TH

• KMID: 2555497
• DOI: http://doi.org/10.3346/jkms.2024.39.e154

Abstract

The emergence of invasive infections attributed to group A Streptococcus (GAS) infections, has resurged since the 1980s. The recent surge in reports of toxic shock syndrome due to GAS in Japan in 2024, while sensationalized in the media, does not represent a novel infectious disease per se, as its diagnosis, treatment, and prevention are already well-established. However, due to signs of increasing incidence since 2011, further research is needed. Health authorities in neighboring countries like The Republic of Korea should not only issue travel advisories but also establish meticulous surveillance systems and initiate epidemiological studies on the genotypic variations of this disease while awaiting various epidemiological research findings from Japan.

Keyword

Streptoccus pyogenes; Toxic Shock Syndrome

Figure

• 

  Fig. 1 Classifications of streptococci.GAS = group A Streptococcus, GBS = group B Streptococcus.

Reference

1. O’ Hern E. Rebecca Craighill Lancefield, pioneer microbiologist. ASM News. 1975; 41(12):805.

2. Breiman RF. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993; 269(3):390–391. PMID: 8418347.

3. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321(1):1–7. PMID: 2659990.

4. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med. 1991; 325(11):783–793. PMID: 1870652.

5. Valenciano SJ, Onukwube J, Spiller MW, Thomas A, Como-Sabetti K, Schaffner W, et al. Invasive group A streptococcal infections among people who inject drugs and people experiencing homelessness in the United States, 2010–2017. Clin Infect Dis. 2021; 73(11):e3718–e3726. PMID: 32803254.

6. Willoughby R, Greenberg RN. The toxic shock syndrome and streptococcal pyrogenic exotoxins. Ann Intern Med. 1983; 98(4):559.

7. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978; 312(8100):1116–1118.

8. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987; 317(3):146–149. PMID: 3299086.

9. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008; 46(7):2359–2367. PMID: 18463210.

10. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009; 9(5):281–290. PMID: 19393958.

11. Nelson GE, Pondo T, Toews KA, Farley MM, Lindegren ML, Lynfield R, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Clin Infect Dis. 2016; 63(4):478–486. PMID: 27105747.

12. Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome. J Infect Dis. 2000; 182(4):1117–1128. PMID: 10979908.

13. Shannon BA, McCormick JK, Schlievert PM. Toxins and superantigens of Group A streptococci. Microbiol Spectr. 2019; 7(1):7.1.12.

14. Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis. 1996; 173(3):619–626. PMID: 8627025.

15. Stevens DL. The flesh-eating bacterium: what’s next? J Infect Dis. 1999; 179(s2 Suppl 2):S366–S374. PMID: 10081509.

16. Swift HF, Wilson AT, Lancefield RC. Typing group a hemolytic streptococci by M precipitin reactions in capillary pipettes. J Exp Med. 1943; 78(2):127–133. PMID: 19871314.

17. Shulman ST, Tanz RR, Kabat W, Kabat K, Cederlund E, Patel D, et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000–2002. Clin Infect Dis. 2004; 39(3):325–332. PMID: 15306998.

18. Kehoe MA, Kapur V, Whatmore AM, Musser JM. Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. Trends Microbiol. 1996; 4(11):436–443. PMID: 8950813.

19. de Crombrugghe G, Baroux N, Botteaux A, Moreland NJ, Williamson DA, Steer AC, et al. The limitations of the rheumatogenic concept for group A streptococcus: systematic review and genetic analysis. Clin Infect Dis. 2020; 70(7):1453–1460. PMID: 31334754.

20. Barnham MR, Weightman NC, Anderson AW, Tanna A. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect. 2002; 8(3):174–181. PMID: 12010172.

21. Ikebe T, Tominaga K, Shima T, Okuno R, Kubota H, Ogata K, et al. Increased prevalence of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012. Epidemiol Infect. 2015; 143(4):864–872. PMID: 25703404.

22. Medical World News. Updated March 2024. Accessed April 10, 2024. https://www.medicalworldnews.co.kr/news/view.php?idx=1510960111&sm=w_total&stx=%EC%9D%BC%EB%B3%B8+%EC%97%B0%EC%87%84%EC%83%81%EA%B5%AC%EA%B7%A0&stx2=&w_section1=&sdate=&edate= .

23. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 1996; 335(8):547–554. PMID: 8684408.

24. Kaul R, McGeer A, Low DE, Green K, Schwartz B, Simor AE. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med. 1997; 103(1):18–24. PMID: 9236481.

25. Stockmann C, Ampofo K, Hersh AL, Blaschke AJ, Kendall BA, Korgenski K, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002–2010. Clin Infect Dis. 2012; 55(4):479–487. PMID: 22534148.

26. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996; 334(4):240–245. PMID: 8532002.

27. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics. 1995; 96(4 Pt 1):758–764. PMID: 7567345.

28. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Infectious Diseases Society of America. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clin Infect Dis. 1997; 25(3):574–583. PMID: 9314443.

29. Traub WH, Leonhard B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy. 1997; 43(1):10–20. PMID: 8996736.

30. Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother. 1993; 32(6):885–891. PMID: 8144429.

31. Park J, Uh Y, Hwang GY, Jang IH, Yoon KJ. Antimicrobial susceptibility of beta-hemolytic streptococci isolated during the period of 1999. Korean J Clin Pathol. 2000; 20(5):475–479.

32. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 1997; 337(7):441–446. PMID: 9250845.

33. Richter SS, Diekema DJ, Heilmann KP, Almer LS, Shortridge VD, Zeitler R, et al. Fluoroquinolone resistance in Streptococcus pyogenes . Clin Infect Dis. 2003; 36(3):380–383. PMID: 12539083.

34. Fay K, Onukwube J, Chochua S, Schaffner W, Cieslak P, Lynfield R, et al. Patterns of antibiotic nonsusceptibility among invasive group a streptococcus infections-United States, 2006–2017. Clin Infect Dis. 2021; 73(11):1957–1964. PMID: 34170310.

35. Vannice KS, Ricaldi J, Nanduri S, Fang FC, Lynch JB, Bryson-Cahn C, et al. Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to β-lactam antibiotics. Clin Infect Dis. 2020; 71(1):201–204. PMID: 31630171.

36. Kim S. Optimal diagnosis and treatment of group A streptococcal pharyngitis. Infect Chemother. 2015; 47(3):202–204. PMID: 26483997.

37. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014; 59(2):147–159. PMID: 24947530.

38. Kwak YG, Choi SH, Kim T, Park SY, Seo SH, Kim MB, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection. Infect Chemother. 2017; 49(4):301–325. PMID: 29299899.

39. Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018; 67(9):1434–1436. PMID: 29788397.

40. Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003; 37(3):333–340. PMID: 12884156.

41. The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients: is prophylaxis warranted? The Working Group on Prevention of Invasive Group A Streptococcal Infections. JAMA. 1998; 279(15):1206–1210. PMID: 9555761.

42. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis. 2002; 35(8):950–959. PMID: 12355382.

43. Adebanjo T, Apostol M, Alden N, Petit S, Tunali A, Torres S, et al. Evaluating household transmission of invasive group A streptococcus disease in the United States using population-based surveillance data, 2013–2016. Clin Infect Dis. 2020; 70(7):1478–1481. PMID: 31408094.

44. Andrejko K, Whittles LK, Lewnard JA. Health-economic value of vaccination against group A streptococcus in the United States. Clin Infect Dis. 2022; 74(6):983–992. PMID: 34192307.

45. Ikebe T, Okuno R, Kanda Y, Sasaki M, Yamaguchi T, Otsuka H, et al. Molecular characterization and antimicrobial resistance of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2013 to 2018. Int J Med Microbiol. 2021; 311(3):151496. PMID: 33756191.

46. Cantagion. Japan Sees New Record Number of Deathly Streptococcal Toxic Shock Infections. Updated January 2018. Accessed April 10, 2024. https://www.contagionlive.com/view/japans-sees-new-record-number-of-deadly-streptococcal-toxic-shock-infections .